{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:29:47Z","timestamp":1794860987000,"version":"4.9.1"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"20","funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["RO1-CA167169"],"award-info":[{"award-number":["RO1-CA167169"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["RO1-CA113580"],"award-info":[{"award-number":["RO1-CA113580"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R21CA178755"],"award-info":[{"award-number":["R21CA178755"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combining standard cytotoxic chemotherapy with BCR-ABL1 tyrosine kinase inhibitors (TKI) has greatly improved the upfront treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, due to the development of drug resistance through both BCR-ABL1\u2013dependent and -independent mechanisms, prognosis remains poor. The STAT5 transcription factor is activated by BCR-ABL1 and by JAK2-dependent cytokine signaling; therefore, inhibiting its activity could address both mechanisms of resistance in Ph+ ALL. We show here that genetic and pharmacologic inhibition of STAT5 activity suppresses cell growth, induces apoptosis, and inhibits leukemogenesis of Ph+ cell lines and patient-derived newly diagnosed and relapsed\/TKI-resistant Ph+ ALL cells ex vivo and in mouse models. STAT5 silencing decreased expression of the growth-promoting PIM-1 kinase, the apoptosis inhibitors MCL1 and BCL2, and increased expression of proapoptotic BIM protein. The resulting apoptosis of STAT5-silenced Ph+ BV173 cells was rescued by silencing of BIM or restoration of BCL2 expression. Treatment of Ph+ ALL cells, including samples from relapsed\/refractory patients, with the PIM kinase inhibitor AZD1208 and\/or the BCL2 family antagonist Sabutoclax markedly suppressed cell growth and leukemogenesis ex vivo and in mice. Together, these studies indicate that targeting STAT5 or STAT5-regulated pathways may provide a new approach for therapy development in Ph+ ALL, especially the relapsed\/TKI-resistant disease.<\/jats:p>\n                  <jats:p>Significance:Suppression of STAT5 by BCL2 and PIM kinase inhibitors reduces leukemia burden in mice and constitutes a new potential therapeutic approach against Ph+ ALL, especially in tyrosine kinase inhibitor-resistant disease. Cancer Res; 78(20); 5793\u2013807. \u00a92018 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-18-0195","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T12:46:37Z","timestamp":1535460397000},"page":"5793-5807","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia"],"prefix":"10.1158","volume":"78","author":[{"given":"Valentina","family":"Minieri","sequence":"first","affiliation":[{"name":"1Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Dominici","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Porazzi","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta A.","family":"Mariani","sequence":"additional","affiliation":[{"name":"2The Queen's Medical Research Institute, Centre for Inflammation Research, The University of Edinburgh, Scotland, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0374-1536","authenticated-orcid":false,"given":"Orietta","family":"Spinelli","sequence":"additional","affiliation":[{"name":"3Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"3Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy."},{"name":"4Universita\u2019 Statale Milano, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke F.","family":"Peterson","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"6Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja T.","family":"Nevalainen","sequence":"additional","affiliation":[{"name":"7Department of Pathology, Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Calabretta","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"2022061706041082000_bib1","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","article-title":"Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia","volume":"91","author":"Faderl","year":"1998","journal-title":"Blood"},{"key":"2022061706041082000_bib2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency by bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"2022061706041082000_bib3","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood"},{"key":"2022061706041082000_bib4","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"key":"2022061706041082000_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24926","article-title":"Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults","volume":"93","author":"El Fakih","year":"2018","journal-title":"Am J Hematol"},{"key":"2022061706041082000_bib6","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061706041082000_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1083-8791(03)70011-1","article-title":"Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation","volume":"9","author":"Stirewalt","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022061706041082000_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022061706041082000_bib9","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"2022061706041082000_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"2022061706041082000_bib11","doi-asserted-by":"crossref","first-page":"e85554","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte","year":"2014","journal-title":"PLoS One"},{"key":"2022061706041082000_bib12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","article-title":"Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"key":"2022061706041082000_bib13","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.4049\/jimmunol.172.8.4770","article-title":"STAT5 activation underlies IL7 receptor-dependent cell development","volume":"172","author":"Goetz","year":"2004","journal-title":"J Immunol"},{"key":"2022061706041082000_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4049\/jimmunol.179.2.1068","article-title":"Stat5 is essential for early B cell development but not for B cell maturation and function","volume":"179","author":"Dai","year":"2007","journal-title":"J Immunol"},{"key":"2022061706041082000_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.coi.2010.02.004","article-title":"STAT5 in B cell development and leukemia","volume":"22","author":"Malin","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"2022061706041082000_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ni.1827","article-title":"Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development","volume":"11","author":"Malin","year":"2010","journal-title":"Nat Immunol"},{"key":"2022061706041082000_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"2022061706041082000_bib18","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","article-title":"Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation","volume":"107","author":"Hoelbl","year":"2006","journal-title":"Blood"},{"key":"2022061706041082000_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"2022061706041082000_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1097-2765(00)00067-8","article-title":"Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL\/JAK2","volume":"6","author":"Schwaller","year":"2000","journal-title":"Mol Cell"},{"key":"2022061706041082000_bib21","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","article-title":"Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation","volume":"20","author":"Xie","year":"2001","journal-title":"Oncogene"},{"key":"2022061706041082000_bib22","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"key":"2022061706041082000_bib23","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"2022061706041082000_bib24","first-page":"447","article-title":"Establishment of a Ph1-positive human cell line (BV173)","volume":"70","author":"Pegoraro","year":"1987","journal-title":"J Natl Cacer Inst"},{"key":"2022061706041082000_bib25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/leu.2009.300","article-title":"ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells","volume":"24","author":"Wu","year":"2010","journal-title":"Leukemia"},{"key":"2022061706041082000_bib26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nprot.2010.43","article-title":"Detection of Mycoplasma in cell cultures","volume":"5","author":"Young","year":"2010","journal-title":"Nat Protoc"},{"key":"2022061706041082000_bib27","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1158\/0008-5472.CAN-09-4229","article-title":"The Polycomb group protein BMI-1 is essential for the growth of multiple myeloma cells","volume":"70","author":"Jagani","year":"2010","journal-title":"Cancer Res"},{"key":"2022061706041082000_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2022061706041082000_bib29","doi-asserted-by":"crossref","first-page":"6552","DOI":"10.1074\/jbc.M510903200","article-title":"Aberrant folding of a mutant Stat5b causes growth hormone insensitivity and proteasomal dysfunction","volume":"281","author":"Chia","year":"2006","journal-title":"J Biol Chem"},{"key":"2022061706041082000_bib30","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2012.19","article-title":"Gfi-1 inhibits proliferation and colony formation of p210BCR\/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1","volume":"26","author":"Soliera","year":"2012","journal-title":"Leukemia"},{"key":"2022061706041082000_bib31","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1535-7163.MCT-14-0883","article-title":"Structure-based screen Identifies a potent small molecule inhibitor of Stat5a\/b with therapeutic potential for prostate cancer and chronic myeloid leukemia","volume":"14","author":"Liao","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2022061706041082000_bib32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"2022061706041082000_bib33","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"2022061706041082000_bib34","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V96.6.2269","article-title":"Bcr\/Abl activates transcription of the Bcl-X gene through STAT5","volume":"96","author":"Gesbert","year":"2000","journal-title":"Blood"},{"key":"2022061706041082000_bib35","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.4049\/jimmunol.164.5.2533","article-title":"The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5","volume":"164","author":"Lord","year":"2000","journal-title":"J Immunol"},{"key":"2022061706041082000_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2022061706041082000_bib37","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2009-03-212852","article-title":"Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"2022061706041082000_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/jm800937p","article-title":"Synthesis and evaluation of novel inhibitors of PIM-1 and PIM-2","volume":"52","author":"Xia","year":"2009","journal-title":"J Med Chem"},{"key":"2022061706041082000_bib39","doi-asserted-by":"crossref","first-page":"33206","DOI":"10.18632\/oncotarget.5091","article-title":"Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias","volume":"6","author":"Curi","year":"2015","journal-title":"Oncotarget"},{"key":"2022061706041082000_bib40","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","article-title":"AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia","volume":"123","author":"Keeton","year":"2014","journal-title":"Blood"},{"key":"2022061706041082000_bib41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20101947","article-title":"Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia","volume":"208","author":"Heltemes-Harris","year":"2011","journal-title":"J Exp Med"},{"key":"2022061706041082000_bib42","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/onc.2008.123","article-title":"Pim kinase-dependent inhibition of c-Myc degradation","volume":"27","author":"Zhang","year":"2008","journal-title":"Oncogene"},{"key":"2022061706041082000_bib43","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.4213","article-title":"PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression","volume":"22","author":"Horiuchi","year":"2016","journal-title":"Nat Med"},{"key":"2022061706041082000_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","article-title":"Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site","volume":"571","author":"Aho","year":"2004","journal-title":"FEBS Lett"},{"key":"2022061706041082000_bib45","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2012-02-412643","article-title":"Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma","volume":"120","author":"Yang","year":"2012","journal-title":"Blood"},{"key":"2022061706041082000_bib46","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2008-10-184515","article-title":"Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia","volume":"114","author":"Tamburini","year":"2009","journal-title":"Blood"},{"key":"2022061706041082000_bib47","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.8.9.8210","article-title":"PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells","volume":"8","author":"Zhang","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"2022061706041082000_bib48","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/jm1001265","article-title":"BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma\/leukemia-2 (Bcl-2) family proteins","volume":"53","author":"Wei","year":"2010","journal-title":"J Med Chem"},{"key":"2022061706041082000_bib49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2022061706041082000_bib50","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"key":"2022061706041082000_bib51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-17-2644","article-title":"Targeting CDK6 and BCL2 exploits the \"MYB addiction\" of Ph+ acute lymphoblastic leukemia","volume":"78","author":"De Dominici","year":"2018","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/20\/5793\/2774051\/5793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/20\/5793\/2774051\/5793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:14:49Z","timestamp":1655471689000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/20\/5793\/631866\/Targeting-STAT5-or-STAT5-Regulated-Pathways"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":51,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2018,10,15]]},"published-print":{"date-parts":[[2018,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-18-0195","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6510594.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6510594","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420215.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420212.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22420221.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]}}}